Roche ditches EGFR drug pact with C4 Therapeutics

Roche has handed back the rights to one of its C4 Therapeutics targets as it tweaks a four-year research pact.

In a short update from C4’s financials, the Watertown, Massachusetts-based preclinical biotech said: “Roche mutually agreed to terminate the Amended and Restated Agreement with respect to the target epidermal growth factor receptor (EGFR). With this termination, C4T regains the right to pursue the target EGFR in products that use degradation as their mode of action.”